公开(公告)号：US11844825B2

公开(公告)日：2023-12-19

申请号：US17314510

申请日：2021-05-07

申请人： Saint Louis University ,  Pontificia Universidad Javeriana

发明人： Adriana M. Montaño-Suarez ,  Angela Catalina Sosa-Molano ,  Alan Knutsen ,  Clifford Bellone ,  Shunji Tomatsu ,  Luis Barrera

IPC分类号： A61K39/00 ,  A61K38/46 ,  A61K9/00

CPC分类号： A61K38/465 ,  A61K9/0019 ,  A61K9/0053 ,  C12Y301/06004

摘要： Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.

公开(公告)号：US20210260172A1

公开(公告)日：2021-08-26

申请号：US17314510

申请日：2021-05-07

申请人： Saint Louis University ,  Pontificia Universidad Javeriana

发明人： Adriana M. Montaño-Suarez ,  Angela Catalina Sosa-Molano ,  Alan Knutsen ,  Clifford Bellone ,  Shunji Tomatsu ,  Luis Barrera

IPC分类号： A61K38/46 ,  A61K9/00

摘要： Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.

公开(公告)号：US20200032229A1

公开(公告)日：2020-01-30

申请号：US16599730

申请日：2019-10-11

申请人： Saint Louis University

发明人： Adriana M. Montaño-Suarez ,  Angela Sosa-Molano

IPC分类号： C12N9/16

摘要： Disclosed are methods and compositions for reduced immunogenic proteins used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are genetically engineered variants of N-acetylgalactosamine-6-sulfatase (GALNS), which are less immunogenetic then wild-type GALNS, but maintain enzymatic activity, and may be used to treat Mucopolysaccharidosis IVA (Morquio A disease, MPS IVA).

公开(公告)号：US10801018B2

公开(公告)日：2020-10-13

申请号：US16599730

申请日：2019-10-11

申请人： Saint Louis University

发明人： Adriana M. Montaño-Suarez ,  Angela Sosa-Molano

IPC分类号： C12N9/16 ,  A61K38/00

摘要： Disclosed are methods and compositions for reduced immunogenic proteins used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are genetically engineered variants of N-acetylgalactosamine-6-sulfatase (GALNS), which are less immunogenetic then wild-type GALNS, but maintain enzymatic activity, and may be used to treat Mucopolysaccharidosis IVA (Morquio A disease, MPS IVA).